Bristol Myers Squibb named Cristian Massacesi, M.D., as executive vice president, chief medical officer and head of development, effective 1 August 2025. He will join the company’s executive leadership team and report directly to board chair and chief executive officer Christopher Boerner. Massacesi spent more than two decades in biopharmaceutical research and development, most recently serving as chief medical officer of AstraZeneca and Alexion and as AstraZeneca’s oncology chief development officer, where he oversaw more than 150 clinical studies and multiple global regulatory approvals. He succeeds Samit Hirawat, M.D., who is stepping down after six years in the role. Hirawat will remain an adviser to Bristol Myers through 1 November 2025 to facilitate the hand-over.